Chromium for Lipid Profile
Chromium's effects on the lipid panel are largely a downstream consequence of its effects on insulin sensitivity, and the size of the effect is small: the authors of a 2021 meta-analysis of 24 trials in type 2 diabetes judged the lipid changes small and possibly below clinical importance. Press's 1990 double-blind crossover trial of 200 mcg chromium picolinate in 28 volunteers at Mercy Hospital and Medical Center, San Diego — reductions of approximately 7% in total cholesterol and 10% in low-density lipoprotein (LDL) cholesterol, with a slight but not statistically significant high-density lipoprotein (HDL) rise — was reported by its authors as showing that chromium picolinate lowers blood lipids in humans. In that 2021 meta-analysis, chromium lowered triglycerides by 6.54 mg/dL and total cholesterol by 7.77 mg/dL and raised high-density lipoprotein by 2.23 mg/dL, with no significant change in low-density lipoprotein; a 2023 umbrella review of eight meta-analyses found no significant effect on any of these blood-lipid measures. The mechanism flows through insulin sensitization of the liver (reduced very-low-density lipoprotein (VLDL) secretion, increased low-density lipoprotein-receptor expression), of adipose tissue (reduced lipolysis and lower free fatty acid flux), and of peripheral tissues (enhanced lipoprotein lipase activity that clears triglyceride-rich particles from the blood). This deep-dive examines the mechanism in detail, walks through the Press 1990 trial and the later meta-analyses, and describes what is known about chromium alongside statins, ezetimibe, and lifestyle change.
Table of Contents
- Why Insulin Resistance Drives Dyslipidemia
- The Press 1990 Mercy Hospital San Diego Trial
- Total Cholesterol Effects
- Low-Density Lipoprotein Cholesterol and the Low-Density Lipoprotein Receptor
- High-Density Lipoprotein Cholesterol and Reverse Transport
- Triglycerides and Very-Low-Density Lipoprotein Metabolism
- Hepatic Mechanism: HMG-CoA, ApoB, Very-Low-Density Lipoprotein Secretion
- Free Fatty Acid Flux from Adipose Tissue
- Meta-Analyses in Type 2 Diabetes Populations
- Combination With Statins, Niacin, and Ezetimibe
- Key Research Papers
- Connections
- Featured Videos
Why Insulin Resistance Drives Dyslipidemia
Dyslipidemia is one of the diagnostic criteria for metabolic syndrome (elevated triglycerides above 150 mg/dL, reduced high-density lipoprotein below 40 mg/dL in men or 50 mg/dL in women), and the lipid abnormalities of metabolic syndrome are mechanistically linked to insulin resistance rather than to dietary cholesterol intake. Understanding why insulin resistance produces a characteristic lipid pattern is essential to understanding why an insulin-sensitizing agent like chromium produces predictable directional effects on the lipid panel.
Insulin normally has three lipid-relevant actions:
- Suppresses hormone-sensitive lipase (HSL) in adipose tissue — in the fed state, insulin shuts down adipocyte lipolysis, reducing free fatty acid (FFA) release into the bloodstream. In insulin-resistant adipose tissue, this suppression fails, and FFA flux remains chronically elevated.
- Suppresses hepatic very-low-density lipoprotein secretion — insulin normally signals the liver to package fatty acids into triglycerides for storage rather than for export. In insulin-resistant liver, the elevated FFA flux from adipose tissue plus the failure of insulin's suppressive signal drives excess very-low-density lipoprotein production. Very-low-density lipoprotein particles are the triglyceride-carrying lipoprotein, so very-low-density lipoprotein excess shows up clinically as hypertriglyceridemia.
- Activates lipoprotein lipase (LPL) in muscle and adipose capillary endothelium — insulin upregulates LPL, the enzyme that hydrolyzes triglyceride from circulating very-low-density lipoprotein and chylomicrons, allowing fatty acid uptake into tissues. In insulin resistance, LPL activity drops, slowing the clearance of triglyceride-rich particles and prolonging postprandial hypertriglyceridemia.
The downstream cascade produces the characteristic "atherogenic dyslipidemia" of metabolic syndrome: elevated triglycerides, reduced high-density lipoprotein cholesterol (because high-density lipoprotein is metabolically consumed in cholesterol-ester transfer protein-mediated exchange with triglyceride-rich particles), and a shift toward small dense low-density lipoprotein particles (which are more atherogenic than large buoyant low-density lipoprotein even at the same low-density lipoprotein-cholesterol concentration). Crucially, this pattern occurs even with normal dietary cholesterol intake — it is driven by impaired insulin signaling, not by what is on the dinner plate.
The proposed mechanism is that, by improving insulin sensitivity at the receptor level, chromium would act on the upstream driver of all three lipid abnormalities at once. The trials do not show a coordinated improvement across the whole lipid panel: in the Press trial, total cholesterol, low-density lipoprotein and apolipoprotein B fell but the high-density lipoprotein rise was not statistically significant, and the later meta-analyses disagree on which lipid measures change, if any (see the meta-analyses section below).
The Press 1990 Mercy Hospital San Diego Trial
Raymond I. Press, Joseph Geller, and Gary W. Evans (the first author was at the Department of Medical Education, Mercy Hospital and Medical Center, San Diego) published the most-cited chromium-and-lipids trial in the Western Journal of Medicine in 1990. The design was rigorous for its era: 28 free-living adults with elevated baseline total cholesterol (above 200 mg/dL) were randomized in a double-blind, placebo-controlled, crossover design. Each subject received 200 mcg/day of chromium (as chromium picolinate, given as chromium tripicolinate) or a placebo for 42 days, separated by a 14-day period off capsules, with each subject acting as their own placebo control.
The results, after pooled analysis of the chromium-on-treatment periods:
- Total cholesterol — reduced from a mean of 270 mg/dL to 250 mg/dL (approximately 7% reduction)
- Low-density lipoprotein cholesterol — reduced from approximately 175 mg/dL to 157 mg/dL (approximately 10% reduction)
- High-density lipoprotein cholesterol — rose slightly but not significantly
- Apolipoprotein B (ApoB) — reduced significantly, consistent with reduced low-density lipoprotein particle number; apolipoprotein B was also the one measure that changed significantly during the placebo period
- Apolipoprotein A-I (ApoA-I) — the principal protein of the high-density lipoprotein fraction; the authors reported a substantial rise
The Press trial was important for several reasons. First, it was designed to test whether chromium picolinate works in humans; the authors described picolinic acid, a metabolite of tryptophan, as forming stable complexes with chromium that improve its bioavailability. Second, it predates the era of widespread statin use, so the effects observed were due solely to chromium rather than to a chromium-statin interaction. Third, the crossover design eliminated between-subject variability as a confounder, increasing statistical power despite a small sample.
Press's interpretation was that chromium acted through insulin-receptor sensitization to reduce hepatic cholesterol synthesis (HMG-CoA reductase activity is partially insulin-regulated) and to enhance hepatic low-density lipoprotein receptor expression. The mechanistic detail has been refined in subsequent decades; whether chromium changes blood lipids at all in the pooled trial evidence is still disputed (see the meta-analyses section below).
Subsequent replication has been variable. A 2014 meta-analysis of 25 trials in diabetes (Suksomboon 2014) found that chromium taken alone lowered triglycerides and raised high-density lipoprotein; other trials and meta-analyses have found smaller or non-significant effects. The pattern across this literature is that lipid effects are clearest in subjects with elevated baseline values and concurrent insulin resistance — consistent with the upstream-driver interpretation.
Total Cholesterol Effects
Total cholesterol is a coarse summary measure that confounds the underlying lipid particles (low-density lipoprotein, high-density lipoprotein, very-low-density lipoprotein remnants, lipoprotein(a)). Modern lipidology has largely moved away from emphasizing total cholesterol in favor of low-density lipoprotein-cholesterol and ApoB. In type 2 diabetes, a 2021 meta-analysis of 24 randomized trials found an average total cholesterol fall of 7.77 mg/dL with chromium, while a meta-analysis of 10 trials found no significant change and a 2023 umbrella review of eight meta-analyses found no significant effect.
The mechanism is partly low-density lipoprotein-mediated (covered below) and partly the reduction in very-low-density lipoprotein remnant particles. Very-low-density lipoprotein remnants contribute to measured total cholesterol but are not separately quantified on a standard lipid panel; they are atherogenic. Insulin sensitization reduces very-low-density lipoprotein secretion from the liver, reduces postprandial very-low-density lipoprotein retention, and thereby reduces very-low-density lipoprotein contribution to total cholesterol.
Total cholesterol alone is a coarse marker. A standard lipid panel also reports the calculated low-density lipoprotein (ApoB can be measured separately), high-density lipoprotein, and triglycerides, and the non-HDL cholesterol value sums the atherogenic particles in one number.
Low-Density Lipoprotein Cholesterol and the Low-Density Lipoprotein Receptor
Low-density lipoprotein cholesterol is the cardiovascular-disease-relevant lipid measure (along with ApoB). Hepatic low-density lipoprotein receptor (LDLR) expression is the rate-limiting step in clearance of circulating low-density lipoprotein particles. The low-density lipoprotein receptor is regulated by intracellular cholesterol concentration (low intracellular cholesterol upregulates LDLR via SREBP-2) and, separately, by insulin signaling. Insulin acutely upregulates LDLR mRNA and protein in hepatocytes, increasing the rate at which the liver removes low-density lipoprotein from the bloodstream.
In insulin resistance, hepatic LDLR upregulation by insulin is impaired, slowing low-density lipoprotein clearance and elevating circulating low-density lipoprotein concentrations. Chromium's restoration of insulin signaling at the liver restores LDLR expression toward normal, increasing low-density lipoprotein clearance. The clinical signature is reduced low-density lipoprotein cholesterol concentration; the underlying mechanism is increased low-density lipoprotein-receptor-mediated removal.
There is a useful conceptual symmetry here with statin drugs. Statins (HMG-CoA reductase inhibitors) work by reducing intracellular hepatic cholesterol synthesis, which depletes intracellular cholesterol, activates SREBP-2, and upregulates LDLR. The endpoint is the same as chromium — more LDLR on the hepatocyte surface — but via a different upstream mechanism. This is why combining chromium with a statin sometimes produces additive lipid lowering in clinical practice (though the additive effect is small relative to the statin effect alone).
Chromium also appears to modestly reduce intestinal cholesterol absorption, possibly through effects on NPC1L1 expression (the target of ezetimibe), though this evidence is preclinical and the magnitude is small. The dominant low-density lipoprotein mechanism remains hepatic LDLR upregulation.
High-Density Lipoprotein Cholesterol and Reverse Transport
High-density lipoprotein is the cardioprotective lipoprotein, responsible for "reverse cholesterol transport" — the removal of cholesterol from peripheral tissues (including arterial-wall foam cells) back to the liver for biliary excretion. Higher high-density lipoprotein is associated with lower cardiovascular risk in observational studies, although pharmacological high-density lipoprotein elevation (CETP inhibitors, niacin in some studies) has not produced reliable cardiovascular benefit in randomized trials, suggesting the association is partly reverse-causation from healthy lifestyle.
Chromium's effects on high-density lipoprotein are small and inconsistent. The 2021 meta-analysis of 24 trials in type 2 diabetes found an average rise of 2.23 mg/dL and the 2014 meta-analysis found a significant rise with chromium taken alone, while a meta-analysis of 10 trials and the 2023 umbrella review found no significant effect. The mechanism, where present, appears to be reduction in CETP-mediated transfer of cholesteryl esters from high-density lipoprotein to triglyceride-rich particles. When circulating triglyceride-rich particles drop (chromium's triglyceride effect), CETP has fewer substrate particles, and high-density lipoprotein retains more of its cholesteryl ester cargo, manifesting as higher high-density lipoprotein cholesterol on the lipid panel.
This is a downstream-of-triglyceride effect rather than a direct high-density lipoprotein-elevating mechanism, which is consistent with the observation that high-density lipoprotein responses to chromium track triglyceride responses across studies. In trials where triglyceride drops are large, high-density lipoprotein elevations tend to be larger; in trials with minimal triglyceride change, high-density lipoprotein change is minimal.
High-density lipoprotein elevation is therefore not the main reported effect of chromium supplementation. Aerobic exercise (described as the largest reliable high-density lipoprotein-raising change), weight loss, and lower carbohydrate intake are the lifestyle changes most often linked to higher high-density lipoprotein.
Triglycerides and Very-Low-Density Lipoprotein Metabolism
Triglycerides are the lipid most often reported to change with chromium, although the effect is small and not found in every analysis. The 2021 meta-analysis of 24 trials in type 2 diabetes found an average fall of 6.54 mg/dL (at the edge of statistical significance, P = 0.050); the 2014 meta-analysis found a significant fall with chromium taken alone, especially chromium picolinate; Balk 2007 found no lipid effect in type 2 diabetes; and the 2023 umbrella review found no significant effect overall, with a fall only in trials using more than 500 mcg a day. This is mechanistically expected because triglycerides are the lipid pool most directly affected by insulin signaling at the liver and adipose tissue.
The triglyceride-lowering mechanism operates at three levels:
- Reduced hepatic very-low-density lipoprotein secretion — restored insulin signaling at the liver suppresses ApoB-100 secretion and very-low-density lipoprotein packaging. Fewer triglyceride-loaded very-low-density lipoprotein particles enter the circulation.
- Reduced substrate supply to liver — improved insulin signaling at adipose tissue suppresses hormone-sensitive lipase, reducing FFA flux to the liver. Less FFA arriving at the liver means less substrate for triglyceride synthesis.
- Increased lipoprotein lipase activity at peripheral tissues — restored insulin signaling at muscle and adipose capillary endothelium upregulates LPL, accelerating hydrolysis and clearance of triglyceride-rich particles from the bloodstream.
The result is reduced rate of very-low-density lipoprotein entry and increased rate of triglyceride-rich particle clearance — a coordinated reduction in circulating triglyceride concentration. Fish oil at 2–4 g/day of combined eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) is another triglyceride-lowering intervention, acting via a different mechanism.
In severe hypertriglyceridemia (above 500 mg/dL, where pancreatitis risk becomes significant), chromium is not an adequate stand-alone treatment — fibrate drugs (gemfibrozil, fenofibrate) or prescription omega-3 fatty acid esters (icosapent ethyl) are the first-line drug treatments. For mild-to-moderate hypertriglyceridemia (150–500 mg/dL), the 2023 umbrella review concluded that chromium “cannot be used as a single therapy to treat adults with lipid abnormalities,” and found a triglyceride fall only at doses above 500 mcg a day.
Hepatic Mechanism: HMG-CoA, ApoB, Very-Low-Density Lipoprotein Secretion
Zooming in on the hepatocyte: the liver is the central organ of lipid metabolism and the principal site of chromium's lipid-modulating effects. Three hepatic processes are particularly relevant:
- HMG-CoA reductase — the rate-limiting enzyme of cholesterol biosynthesis. HMG-CoA reductase is regulated by intracellular cholesterol concentration (sterol-mediated feedback), by SREBP-2 (the master transcription factor for cholesterol synthesis genes), and partially by insulin (insulin signaling has modest direct and indirect effects on hepatic HMG-CoA reductase activity). Chromium's contribution here is small relative to statin effect but is the proposed partial mechanism for the total cholesterol reduction observed in the Press 1990 trial.
- Apolipoprotein B-100 (ApoB-100) — the obligate structural protein of very-low-density lipoprotein and low-density lipoprotein particles. Each very-low-density lipoprotein or low-density lipoprotein particle contains exactly one ApoB-100 molecule, so ApoB concentration directly reflects atherogenic particle number. ApoB-100 secretion from hepatocytes is suppressed by insulin in the normal state; in insulin resistance, this suppression fails, and ApoB-100 secretion rises. Chromium's restoration of hepatic insulin signaling restores partial ApoB-100 secretion suppression. Several studies measure ApoB as a more sensitive secondary endpoint and report reductions consistent with the underlying mechanism.
- Very-low-density lipoprotein packaging and secretion — the assembly of very-low-density lipoprotein particles in the hepatocyte endoplasmic reticulum requires ApoB-100 plus triglyceride plus cholesteryl ester, and the rate-limiting step is microsomal triglyceride transfer protein (MTP). Insulin signaling represses MTP transcription and reduces ApoB-100 stability, reducing the overall very-low-density lipoprotein output. Restored insulin signaling from chromium supplementation translates to reduced very-low-density lipoprotein output, which is the proximate cause of the observed triglyceride reduction.
The integrated picture is that chromium acts primarily at the hepatocyte, primarily through restoration of insulin signaling, and the lipid-panel effects are downstream consequences. This is mechanistically distinct from drugs that act on lipid metabolism enzymes directly (statins, fibrates, ezetimibe, PCSK9 inhibitors) and is the proposed reason any effects would be modest and spread across the lipid panel rather than large on a single lipid parameter.
Free Fatty Acid Flux from Adipose Tissue
The other major chromium-relevant lipid process is adipose tissue free fatty acid release. In the fed state, insulin normally suppresses adipocyte lipolysis by phosphorylating hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) into their inactive forms. In insulin-resistant adipose tissue, this suppression fails, and FFA continues to flow out of adipocytes even in the postprandial state when it would normally be stored as triglyceride.
This chronic FFA over-supply has downstream consequences: hepatic uptake of excess FFA drives very-low-density lipoprotein overproduction (as described above), muscle uptake of excess FFA drives intramyocellular lipid accumulation and worsening of muscle insulin resistance (lipotoxicity), and pancreatic beta-cell uptake of excess FFA contributes to lipotoxic beta-cell dysfunction.
Chromium's restoration of insulin signaling at adipose tissue tends to suppress inappropriate lipolysis and reduce FFA flux. This is a slow effect that builds over weeks of supplementation rather than acutely; the clinical signature is reduced fasting FFA concentration and reduced 24-hour FFA AUC.
Reducing FFA flux also relieves the secondary insulin resistance at muscle and liver that FFA over-supply was inducing. This is one mechanism behind the observation that long-term chromium supplementation produces progressively larger effects on glucose disposal — the early benefit is direct insulin-receptor amplification, but a slower-developing benefit is reversal of lipotoxic insulin resistance at distant tissues.
Meta-Analyses in Type 2 Diabetes Populations
Several meta-analyses have pooled the chromium trials in diabetes. Not all of them measured lipids, and their lipid findings disagree:
- Balk et al. 2007 (Diabetes Care) — pooled 41 randomized trials (almost half of poor quality) including diabetic and non-diabetic subjects. In type 2 diabetes, chromium lowered hemoglobin A1c (HbA1c) by 0.6 percentage points and fasting glucose by 1.0 mmol/L but did not change lipids; in people without diabetes it had no significant effect on lipids or glucose. This is the most widely cited chromium meta-analysis.
- Suksomboon, Poolsup, Yuwanakorn 2014 (J Clin Pharm Ther) — pooled 25 randomized trials of chromium in diabetes. Chromium lowered hemoglobin A1c by 0.55 percentage points and fasting glucose by 1.15 mmol/L. Chromium taken alone also significantly lowered triglycerides and raised high-density lipoprotein, with the glucose and triglyceride effects seen especially with chromium picolinate; the abstract reports no total-cholesterol or low-density lipoprotein effect. Adverse events were no more common than on placebo.
- Yin and Phung 2015 (Nutrition Journal) — pooled 14 randomized trials (875 people with type 2 diabetes) and analyzed only hemoglobin A1c and fasting glucose, not lipids. Chromium yeast, brewer's yeast and chromium picolinate had no statistically significant effect on hemoglobin A1c; only brewer's yeast lowered fasting glucose (by 19.23 mg/dL).
- Asbaghi et al. 2021 (J Trace Elem Med Biol) — the lipid-specific meta-analysis: 24 randomized trials in type 2 diabetes. Chromium lowered triglycerides by 6.54 mg/dL (P = 0.050) and total cholesterol by 7.77 mg/dL and raised high-density lipoprotein by 2.23 mg/dL; the 8.54 mg/dL fall in low-density lipoprotein was not statistically significant. The authors noted that the lipid-lowering effects “were small and may not reach clinical importance.”
- Zhao et al. 2022 (Biol Trace Elem Res) — 10 randomized trials with 509 people with type 2 diabetes. Chromium lowered hemoglobin A1c, but made no statistically significant difference to fasting glucose, triglycerides, total cholesterol, low-density lipoprotein or high-density lipoprotein.
- Vajdi et al. 2023 (Biol Trace Elem Res) — an umbrella review pooling eight meta-analyses of chromium trials in adults. It found no significant effect on triglycerides, total cholesterol, low-density lipoprotein or high-density lipoprotein; only in the subgroup given more than 500 mcg a day did triglycerides fall. The authors concluded that chromium “cannot be used as a single therapy to treat adults with lipid abnormalities.”
Across these meta-analyses the lipid findings are inconsistent. The largest lipid-specific analysis (Asbaghi 2021) found small falls in triglycerides and total cholesterol and a small high-density lipoprotein rise, but no low-density lipoprotein effect, and its authors judged the changes small; Balk 2007 and Zhao 2022 found no significant lipid effect in type 2 diabetes; and the 2023 umbrella review found no significant effect on any lipid measure. The more consistent finding is a modest fall in hemoglobin A1c in people with diabetes, reported by Balk 2007, Suksomboon 2014 and Zhao 2022 (but not by Yin and Phung 2015).
Critical caveats from the meta-analyses: heterogeneity across included trials is substantial; not every individual trial replicates the pooled effect; chromium form (picolinate vs polynicotinate vs chloride) was not always specified in older trials; dose ranged across two orders of magnitude (16 mcg/day to 1,000 mcg/day); and many included trials had modest sample sizes and follow-up durations.
Combination With Statins, Niacin, and Ezetimibe
For most adult patients with dyslipidemia warranting pharmacologic treatment, statin therapy (atorvastatin, rosuvastatin, simvastatin, pravastatin) is first-line. Chromium is not a substitute for statins in people with significant cardiovascular risk — in the 2021 meta-analysis of 24 trials in type 2 diabetes, chromium's average low-density lipoprotein change (−8.54 mg/dL) was not statistically significant, while moderate-intensity statin therapy lowers low-density lipoprotein by 30–50%.
Chromium has been studied as an adjunct to statin therapy in a small number of trials. The pattern observed is additive but not synergistic: combination produces incremental low-density lipoprotein and triglyceride reduction beyond statin alone, but the magnitude of additive benefit is small (typically 5–10 mg/dL further low-density lipoprotein reduction). The 2023 umbrella review of eight meta-analyses found no significant overall effect of chromium on blood lipids.
The combination with niacin (vitamin B3) is interesting because chromium polynicotinate is structurally a chromium-niacin complex, and niacin itself is a lipid-modulating intervention (reduces low-density lipoprotein and triglycerides, raises high-density lipoprotein at gram-per-day doses). Whether chromium polynicotinate produces lipid effects beyond what its niacin content alone would predict is an unresolved question. Most clinical trials of chromium polynicotinate use doses providing only milligrams of niacin (well below the gram doses needed for niacin's independent lipid effect), so the lipid effects observed are likely due to the chromium rather than the niacin moiety. At therapeutic doses (1–3 g/day), niacin can raise uric acid, blood glucose, and liver enzymes, with or without chromium.
Ezetimibe inhibits intestinal cholesterol absorption via NPC1L1. There is no published clinical trial of chromium-ezetimibe combination; the two interventions act through different mechanisms (gut-luminal absorption inhibition vs hepatic insulin sensitization), so an additive effect would be expected. Whether the additive effect is clinically meaningful is untested.
PCSK9 inhibitors (alirocumab, evolocumab) are injectable monoclonal antibodies for refractory hypercholesterolemia or familial hypercholesterolemia. Chromium has not been studied as an adjunct to PCSK9 therapy. The mechanisms are independent and additive effects would be expected, but the clinical importance is small relative to the dominant PCSK9 effect.
This content is provided for informational purposes only and does not constitute medical advice. In the meta-analyses described above, chromium's effects on blood lipids were small or not significant, and chromium is not a substitute for prescribed lipid-lowering medicines.
Key Research Papers
- Press RI, Geller J, Evans GW (1990). The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. Western Journal of Medicine 152(1):41-45. — PubMed PMID: 2408233
- Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007). Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 30(8):2154-2163. — DOI: 10.2337/dc06-0996. — doi:10.2337/dc06-0996
- Suksomboon N, Poolsup N, Yuwanakorn A (2014). Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. Journal of Clinical Pharmacy and Therapeutics 39(3):292-306. — PubMed PMID: 24635480
- Yin RV, Phung OJ (2015). Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutrition Journal 14:14. — PubMed PMID: 25971249
- Abraham AS, Brooks BA, Eylath U (1992). The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 41(7):768-771. — PubMed PMID: 1619996
- Riales R, Albrink MJ (1981). Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. American Journal of Clinical Nutrition 34(12):2670-2678. — PubMed PMID: 7032273
- Cheng N, Zhu X, Shi H, Wu W, Chi J, Cheng J, Anderson RA (1999). Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. Journal of Trace Elements in Experimental Medicine 12(2):55-60. — doi:10.1002/(SICI)1520-670X(1999)12:2<55::AID-JTRA2>3.0.CO;2-G
- Ngala RA, Awe MA, Nsiah P (2018). The effects of plasma chromium on lipid profile, glucose metabolism and cardiovascular risk in type 2 diabetes mellitus. PLoS ONE 13(7):e0197977. — PubMed PMID: 29975702
- Asbaghi O, Naeini F, Ashtary-Larky D, et al. (2021). Effects of chromium supplementation on lipid profile in patients with type 2 diabetes: a systematic review and dose-response meta-analysis of randomized controlled trials. Journal of Trace Elements in Medicine and Biology 66:126741. — PubMed PMID: 33813266
- Hua Y, Clark S, Ren J, Sreejayan N (2012). Molecular mechanisms of chromium in alleviating insulin resistance. Journal of Nutritional Biochemistry 23(4):313-319. — PubMed PMID: 22423897
- Ginsberg HN, Zhang YL, Hernandez-Ono A (2005). Regulation of plasma triglycerides in insulin resistance and diabetes. Archives of Medical Research 36(3):232-240. — PubMed PMID: 15925013
- Adams JF, Engstrom A (2000). Helping consumers achieve recommended intakes of whole grain foods. Journal of the American College of Nutrition 19(3 Suppl):339S-344S. — PubMed PMID: 10875607
- Zhao F, Pan D, Wang N, Xia H, Zhang H, Wang S, Sun G (2022). Effect of chromium supplementation on blood glucose and lipid levels in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Biological Trace Element Research 200(2):516-525. — PubMed PMID: 33783683
- Vajdi M, Musazadeh V, Karimi A, Heidari H, Tarrahi MJ, Askari G (2023). Effects of chromium supplementation on lipid profile: an umbrella of systematic review and meta-analysis. Biological Trace Element Research 201(8):3658-3669. — PubMed PMID: 36376714
PubMed Topic Searches
Connections
- All Minerals
- Chromium Overview
- Chromium Benefits Hub
- Chromium for Blood Sugar
- Chromium for Insulin Sensitivity
- Chromium for Weight Management
- Cardiovascular Disease
- Atherosclerosis
- Metabolic Syndrome
- Type 2 Diabetes
- Niacin / Vitamin B3
- Lipid Panel
- Omega-3 Fatty Acids
- Berberine
- Cinnamon
- Magnesium
- Insulin Resistance
- Blood Sugar
- Obesity
- Deficiency
- Toxicity
- History